Although NTRK fusions are found in a small subset of ovarian cancer patients, the favorable objective response, disease agnostic indication, and few adverse effects with TRK inhibitors should make them a viable choice for patients with metastatic disease and no standard therapy available. The gene discussed is NTRK1; the disease is ovarian carcinoma.